NPCE.US Neuropace Inc

Healthcare Health Care Equipment & Supplies USA Stocks
7.56 USD
Close of Nov 15, 2026
5.46 19.60
Market cap
USD 260M
P/E
-
P/B
22.75x
ROE
-187.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NPCE.US undervalued?

Graham number

The Graham number of Neuropace Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Neuropace Inc fundamental analysis

No fundamental analysis for Neuropace Inc yet.

Neuropace Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Neuropace Inc

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tabl…

Full company profile